Rafael Holdings completes phase 3 study for rare disease treatment

June 10, 2026 7:30 AM

Rafael Holdings Inc. (NYSE: RFL) completed the final patient visit for its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found